Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers

17. januar 2017 opdateret af: TotipotentRX Cell Therapy Pvt. Ltd.

To Demonstrate the Safety and Efficacy of Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers

The purpose of this study is to evaluate the safety and efficacy of autologous PRP injection in combination with topical application of PRP gel in treating chronic or non-healing ulcers on lower extremity using a rapid, intra-operative, point-of-care technology at the patient's bedside.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

Platelet Rich Plasma (PRP) therapy is an innovative treatment that uses body's own cells to relieve pain and promote accelerated healing of Non-healing Foot Ulcer /Wound. The body's response to any tissue injury is to deliver platelets, which play an instrumental role in the normal healing process by secreting growth factors and attracting stem cells-critical components of the healing cascade.

Any wound or ulcer on skin that has been present for 4-5 weeks duration, without healing is called a non-healing ulcer. Non-healing ulcers include venous, arterial, diabetic, pressure and traumatic ulcers. Cellular therapies using Autologous Platelet Rich Plasma provides new options for wound healing. The efficacy of the treatment has been proven in surgical applications, in the treatment of severe burns and in transplantation of cells and tissues.

Local application of a solution of plasma enriched in platelets derived from the patient's blood intends to trigger the healing process in non-responsive chronic wound, increase the wound repair rate and reduce pain. PRP is a good option for non-healing wounds because it utilizes the body's natural healing processes to jump-start wound healing. Plasma which contains very valuable growth factors is separated from other blood components utilizing a point of care technology based on density gradient centrifugation. The platelet rich plasma is harvested and then activated by a mixture of human thrombin and calcium chloride for initiating the healing cascade followed by PRP injection directly into the ulcer/wound periphery or spread over a wound in the form of a PRP gel.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

24

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Delhi, Indien, 110025
        • Fortis Escorts Heart Institute and Research Centre

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male or Female 18 to 85 years of age
  • Chronic or Non-healing ulcer of any etiology (venous, pressure, arterial or diabetic foot ulcer) which is at least 4 weeks old
  • Index foot ulcer located on the plantar, medial or lateral aspect of the foot (including all toe surfaces)
  • Wound area (length x width) measurement must be between 0.5 cm^2 and 10 cm^2, inclusive
  • If more than one non-healing ulcers is present, the largest wound will be selected
  • Index ulcer must be clinically non-infected
  • Full-thickness ulcer without exposure of bone, muscle, ligament or tendon
  • Written informed consent must be obtained from either the patient or the patients legally acceptable representative prior to enrollment

Exclusion Criteria:

  • Patients with known sensitivity to components of the PRP kit (calcium chloride, thrombin, acid citrate dextrose solution A (ACD-A))
  • Smokers and individuals with systemic disease or history of anticoagulant, immuno-suppressive or antibiotic therapy in the last 3 months
  • Platelet count < 105 x 10^3/ uL (according to CBC)
  • Hemoglobin level < 10 g/dL (according to CBC)
  • Wound is clinically infected
  • Presence of platelet dysfunction syndrome or critical thrombocytopenia
  • Bleeding disorders, collagen vascular disease or severe cardiovascular disorder
  • Any malignancy other than non-melanoma skin cancer
  • Patient is currently receiving or has received radiation or chemotherapy within 3 months prior to treatment
  • If female, patient is pregnant, nursing or plans to become pregnant during the duration of the study
  • Subject has inadequate venous access for blood draw required for PRP preparation
  • Any chronic condition requiring the use of systemic corticosteroids 30 days prior to study entry and anytime during the course of the study
  • Subject is on dialysis or has uncontrolled sugar levels

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Autologous PRP Gel and PRP Injection
Autologous PRP will be prepared using an advanced rapid point-of-care technology, the Res-Q™ 60 PRP system at the patient's bed side. The Activator solution for PRP gel will be prepared by combining human thrombin (500 IU/ml) with 1% Calcium Chloride.

Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer.

Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound.

Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Wound/ Ulcers Healed
Tidsramme: 24 weeks
The number of wound/ ulcers healed will be assessed by visual inspection of reduction in wound size at 24 weeks post PRP therapy
24 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to Ulcer Healing
Tidsramme: 24 weeks
The average time taken for the ulcers to heal post PRP administration
24 weeks
Reduction in Pain using VAS pain score
Tidsramme: 24 weeks
Improvement in Pain and discomfort following PRP therapy
24 weeks
Changes in Quality of Life using the SF-36 Questionnaire
Tidsramme: 24 weeks
Improvement in Quality of Life of the patients following PRP therapy
24 weeks
Number of participants with treatment-related Adverse Events
Tidsramme: 24 weeks
Safety of the treatment will be assessed by measuring the number of treatment related adverse events and adverse reactions during the follow-up period
24 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Dr. Suhail N Bukhari, MBBS, DNB, Fortis Escorts Heart Institute and Research Centre

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. juni 2014

Primær færdiggørelse (Faktiske)

1. april 2016

Studieafslutning (Faktiske)

1. maj 2016

Datoer for studieregistrering

Først indsendt

4. januar 2017

Først indsendt, der opfyldte QC-kriterier

17. januar 2017

Først opslået (Skøn)

20. januar 2017

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

20. januar 2017

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. januar 2017

Sidst verificeret

1. januar 2017

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • TPRX/PRP/NHU/141005

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Kronisk sår

Kliniske forsøg med Autologous PRP Gel and PRP Injection

Abonner